Reading ONCO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ONCO free→Reading ONCO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ONCO free→QuarterlyIQ Insights · ONCO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Resignation of Andrew Oakley and Thomas Meier as Directors; Elections of Sammy Dorf as Chairman of the Board Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of Directors (the “ Board ”) of Onconetix, Inc, a Delaware corporation (the “ Company ”), of their resignation from the Board. As a result of their resignation fro…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of David White as Chief Executive Officer On March 18, 2026, the Board of Directors (the “ Board ”) of Onconetix, Inc, a Delaware corporation (the “ Company ”) appointed David White as Chief Executive Officer of the Company effective as of that date. Karina Fedasz, the immediate past Interim Chief Executive Officer of the Company, will c…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of David White as Chief Executive Officer On March 18, 2026, the Board of Directors (the “ Board ”) of Onconetix, Inc, a Delaware corporation (the “ Company ”) appointed David White as Chief Executive Officer of the Company effective as of that date. Karina Fedasz, the immediate past Interim Chief Executive Officer of the Company, will c…
Other Events Press Release On February 12, 2026, Onconetix issued a press release announcing the entry into the Share Exchange Agreement (the “ Press Release ”). The Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Business of Realbotix Realbotix is a technology company focused on designing and manufacturing artificial intelligence (“ AI ”) powered humanoid robots built for meaningful human interaction such as customer service, hospitality and healthcare.…
Entry into a Material Definitive Agreement. This section describes the material provisions of the Share Exchange Agreement (as defined below) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of the Share Exchange Agreement, a copy of which is attached hereto as Exhibit 2.1. Unless otherwise defined herein, the capitalized terms used below are defined in the Share Exchange Agreement. Share Exchange A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2025, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”) held a meeting to review and approve certain executive compensation matters. At the meeting, the Committee approved a bonus of $45,000 for Karina Fedasz in recognition of her service as the Company’s Interim C…
Entry Into a Material Definitive Agreement On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products…
Unregistered Sales of Equity Securities. The information provided in
Entry into a Material Definitive Agreement. PIPE Financing On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Compa…
shall have the meanings ascribed to such terms in the Merger Agreement. On September 5, 2025, Ocuvex received written notice from the Company that the Company had received a Parent Acquisition Proposal and determined that such Parent Acquisition Proposal is a Parent Superior Proposal. On September 5, 2025, the Board of Directors of the Company made a Parent Adverse Recommendation Change. Effective September 24, 2025, pursuant to Section 9.01(a) of the Merger Agreement, the Parties entered int…
Unregistered Sales of Equity Securities. The information provided in
Entry into a Material Definitive Agreement. PIPE Financing On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock o…
Entry Into a Material Definitive Agreement On September 17, 2025, Proteomedix AG (“ Proteomedix ”), a wholly-owned subsidiary of Onconetix, Inc. (the “ Company ”), entered into a licensing agreement (the “ Agreement ”) with Immunovia, Inc. (“ Immunovia ”), a pancreatic cancer diagnostics company based in Lund, Sweden. Under the Agreement, Proteomedix will provide Immunovia with master cell lines required to produce antibodies for three of the five biomarkers used in the PancreaSure test, as w…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in
Entry Into a Material Definitive Agreement Keystone Capital LLC Promissory Note and KCP Fund I Promissory Note On August 28, 2025, Onconetix, Inc. (the “ Company ”) issued promissory note to each of (i) Keystone Capital Partners, LLC (“ Keystone ” and such note, the “ Keystone Note ”) and (ii) KCP Fund I, LLC, an affiliate of Keystone (the “ KCP Note ”, and together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount of $58,823.53. The…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 10, 2025, Ajit Singh resigned as a member of the Board of Directors of the Company. The Company believes that there are no matters requiring disclosure under Item 5.02(a)(iii) of Current Report on Form 8-K.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in
Entry Into a Material Definitive Agreement Keystone Capital LLC Promissory Note On August 6, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note (the “ Keystone Note” ) to Keystone Capital Partners, LLC (“ Keystone ”) with original issue discount of $17,647.06, in an aggregate principal amount of $117,647.06. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from its equity line of credit with Keystone (the “ ELOC ”) and (ii) March 6…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 12, 2025, Onconetix’s Board of Directors (the “ Board ”) elected Andrew Oakley, 63, an existing member of the Board and Onconetix’s Non-Executive Chairman, as Lead Independent Director. Mr. Oakley, one of Onconetix’s directors and its Non-Executive Chairman since February 2025, is an experienced pharmaceutical and biotech industry profession…
Entry into a Material Definitive Agreement. General Description of the Agreement and Plan of Merger On July 16, 2025, Onconetix, Inc, a Delaware corporation (“ Onconetix ” or “ Parent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among (i) Parent, (ii) Onconetix Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“ Merger Sub ”), (iii) Ocuvex Therapeutics, Inc., a Delaware corporation (“ Ocuvex ” or the “ Company ”) a…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in
Entry Into a Material Definitive Agreement On June 5, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note to Keystone Capital Partners, LLC with original issue discount of $22,058.82, in an aggregate principal amount of $147,058.82. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from the ELOC and (ii) March 5, 2026, subject to mandatory prepayment in the event that the Company raises sufficient additional capital through other sec…
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Entry Into a Material Definitive Agreement On May 16, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note to Keystone Capital Partners, LLC (the “ Investor ”) with original issue discount of $44,117.65, in an aggregate principal amount of $294,117.65 (the “ Note ”). The Note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from its Equity Line of Credit with the Investor or (ii) February 16, 2026, subject to mandatory prepayment in the event…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 20, 2025, Onconetix, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Quarterly Report on Form 10-Q for the three months ended Marc…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.